Skip to main content

8110 Gatehouse Road, Falls Church, VA 22042

A221505 – Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

General Information

Age Group

Adult

Status

Recruiting

Protocol Number

NCT03414970

Background Information

This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.

Offered At

Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031
A department of Inova Fairfax Hospital

Eligibility Information

  • Participant has/had histologically confirmed invasive carcinoma of the breast
  • No prior radiation therapy to the chest, neck or axilla
  • No active collagen vascular diseases, such as: systemic lupus erythematous, scleroderma, or dermatomyositis
  • Participant must have undergone immediate reconstruction at the time of mastectomy or be planning to undergo reconstruction within 8 months after radiation
  • Additional eligibility in protocol

Ineligibility Information

  • History of prior or concurrent contralateral invasive breast cancer; benign breast disease, LCIS or DCIS of contralateral breast
  • Positive inked histologic margins from mastectomy pathology (no invasive cells at margin)
  • For patients with diabetes, hemoglobin A1C test must have been performed =< 90 days prior to registration
  • Additional exclusions in protocol

For more information go to: https://clinicaltrials.gov/ct2/show/NCT03414970